572924-87-9

Upstream product

• 1885-14-9 phenyl chloroformate 
• 20859-02-3 L-tert-Leucine 
• 62965-35-9 N-tert-butyloxycarbonyl-L-tert-leucine 
• 154092-61-2 (S)-benzyl 2-(tert-butoxycarbonylamino)-3,3-dimethylbutanoic acid 

Downstream Products

• 572924-88-0 cyclopentyl urea-Tbg-OBn 
• 801282-70-2 C₂₀H₃₀N₂O₃ 
• 1035377-62-8 (S)-benzyl 2-(3-(cyclopropylmethyl)ureido)-3,3-dimethylbutanoate 

Relevant academic research and scientific papers

HCV INHIBITORS

The present invention is directed to compounds that are antiviral agents. Specifically, the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

HEPATITIS C INHIBITOR PEPTIDE ANALOGS

The invention relates to compounds of formula (I) wherein R', R2, R3, R4, R5, R6, Y, n and m are as defined herein. The compounds are useful for the treatment and prevention of hepatitis C viral infections in mammals by inhibiting HCV NS3 protease. The invention further relates to azalactone compounds of the formula (III) which can be reacted with an amide anion to produce the compounds of formula (I).

HEPATITIS C INHIBITOR COMPOUNDS

Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.

Hepatitis C inhibitor compound

Compounds of formula (I): wherein B, X, R3, R21, R22, R1 and Rc are defined herein. The compounds are useful as inhibitors of HCV NS3 protease.